Who does this study affect: People with untreated, advanced non-small cell lung cancer (NSCLC). What did this study find: Results from the phase III CHOICE-01 clinical trial in China show that adding the immunotherapy drug toripalimab (TuoYi) to chemotherapy in people with untreated, advanced NSCLC slowed cancer growth and helped them live longer, particularly if their tumors had certain biomarkers, which are mutations, genes, or patterns found in a tumor’s […]